We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-9.98%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.17B
AUM Growth
-$1.61B
Cap. Flow
-$473M
Cap. Flow %
-7.66%
Top 10 Hldgs %
32.27%
Holding
171
New
12
Increased
33
Reduced
25
Closed
28

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$89.7M
2
PFE icon
Pfizer
PFE
+$66.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$65.8M
4
ARGX icon
argenx
ARGX
+$49.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$47.1M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$136M
2
BMY icon
Bristol-Myers Squibb
BMY
+$116M
3
HCA icon
HCA Healthcare
HCA
+$100M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$82.9M
5
SVA
Sinovac Biotech, Ltd
SVA
+$72.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$340M 5.52%
6,028,307
– –
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$231M 3.75%
2,196,555
-303,500
-12% -$29.6M
BSX icon
3
Boston Scientific
BSX
$68.5B
$204M 3.3%
4,599,500
-952,800
-17% -$41.3M
PFE icon
4
Pfizer
PFE
$144B
$202M 3.28%
3,905,500
+1,290,100
+49% +$66.9M
THRX
5
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$196M 3.19%
17,041,668
+203,000
+1% +$2.17M
BMY icon
6
Bristol-Myers Squibb
BMY
$130B
$190M 3.09%
2,607,700
-1,732,100
-40% -$116M
HUM icon
7
Humana
HUM
$46.7B
$166M 2.69%
381,700
+63,400
+20% +$26.5M
ISRG icon
8
Intuitive Surgical
ISRG
$130B
$161M 2.61%
534,200
+160,400
+43% +$46.9M
UNH icon
9
UnitedHealth
UNH
$389B
$150M 2.43%
294,200
+23,200
+9% +$11.2M
ACET icon
10
Adicet Bio
ACET
$76.7M
$149M 2.41%
465,446
– –
ABBV icon
11
AbbVie
ABBV
$465B
$148M 2.41%
915,600
-153,200
-14% -$22.3M
PMVP icon
12
PMV Pharmaceuticals
PMVP
$58.7M
$143M 2.31%
6,855,423
-475,000
-6% -$8.38M
EWTX icon
13
Edgewise Therapeutics
EWTX
$4.34B
$135M 2.19%
13,944,680
– –
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$134M 2.17%
1,630,500
+204,100
+14% +$20.9M
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$12B
$127M 2.06%
1,647,030
+786,150
+91% +$65.8M
EW icon
16
Edwards Lifesciences
EW
$48.2B
$124M 2.01%
1,051,300
-24,900
-2% -$2.79M
SYK icon
17
Stryker
SYK
$133B
$122M 1.98%
457,100
-8,200
-2% -$2.12M
ARQT icon
18
Arcutis Biotherapeutics
ARQT
$3.55B
$117M 1.9%
6,073,850
– –
IOVA icon
19
Iovance Biotherapeutics
IOVA
$2.1B
$110M 1.79%
6,633,006
+295,306
+5% +$4.57M
VRTX icon
20
Vertex Pharmaceuticals
VRTX
$124B
$104M 1.69%
400,200
-257,900
-39% -$61.2M
SGEN
21
DELISTED
Seagen Inc. Common Stock
SGEN
$96.2M 1.56%
667,700
+12,100
+2% +$1.64M
KROS icon
22
Keros Therapeutics
KROS
$199M
$91.3M 1.48%
1,679,417
– –
GH icon
23
Guardant Health
GH
$19B
$87.8M 1.42%
1,325,400
+98,000
+8% +$6.71M
BHVN
24
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$85.3M 1.38%
+719,034
New +$89.7M
TCDA
25
DELISTED
Tricida, Inc. Common Stock
TCDA
$84.5M 1.37%
10,280,947
– –
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2022 Portfolio in Review

As of Q1 2022, OrbiMed held 171 positions worth $6.17B, down 21% from $7.78B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed withdrew a net $473M in Q1 2022, closing 28 positions and reducing 25 holdings. Its most notable exit was Merck, an estimated $136M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials.

Against the trend, OrbiMed opened a new position in Biohaven Pharmaceutical Holding Company Ltd. worth $85.3M.

  • OrbiMed's largest Q1 2022 buy was Biohaven Pharmaceutical Holding Company Ltd.: 719,034 shares worth $85.3M.
  • OrbiMed added most to Pfizer in Q1 2022, an estimated $66.9M increase.
  • OrbiMed's biggest Q1 2022 reduction was Bristol-Myers Squibb, cutting an estimated $116M.
  • OrbiMed fully exited Merck in Q1 2022, selling an estimated $136M.
  • OrbiMed's ten largest holdings make up 32% of its $6.17B portfolio in Q1 2022.
  • OrbiMed opened 12 new positions and closed 28 in Q1 2022.
  • OrbiMed's portfolio value fell 21% quarter-over-quarter to $6.17B.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.